Akorn gets approval for Sufenta injection

By Elaine Rigoli

Tampa, Fla., June 7 - Akorn, Inc. has received approval for a supplemental New Drug Application for Sufenta injection.

Sufenta has been off the market since 2002 due to compliance issues associated with the Decatur, Ill., manufacturing facility.

Buffalo Grove, Ill.-based Akorn manufactures and markets sterile specialty pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.